Skip to search formSkip to main contentSkip to account menu

zalutumumab

Known as: HuMax-EGFr, 2F8 
A fully human IgG1 monoclonal antibody against epidermal growth factor receptor (EGFR) with potential antineoplastic activity. EGFR is a cell surface… 
National Institutes of Health

Related topics

Related topics

4 relations
Antibody-Dependent Cellular CytotoxicityEGFR protein, humanantigen binding

Broader (1)

Monoclonal Antibodies

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2015
2015
OC-009: Update of the randomised phase III trial DAHANCA 19: Primary C-RT or RT and zalutumumab for squamous cell carcinomas of head and neck
2014
2014
Three-Dimensional Histologic Validation of High-Resolution SPECT of Antibody Distributions Within Xenografts
Longitudinal imaging of intratumoral distributions of antibodies in vivo in mouse cancer models is of great importance for… 
2013
2013
DAHANCA 19: First results of a randomized phase III study of the importance of the EGFR-inhibitor zalutumumab for the outcome of primary curative radiotherapy for squamous cell carcinoma of the head…
2012
2012
Biologic Therapy in Head and Neck Cancer: A Road with Hurdles
The epidermal growth factor receptor (EGFR) is overexpressed in the vast majority of cases of squamous cell carcinoma of the head… 
2011
2011
Complement‐mediated tumor‐specific cell lysis by antibody combinations targeting epidermal growth factor receptor (EGFR) and its variant III (EGFRvIII)
Monoclonal antibodies (mAb) against variant III of epidermal growth factor receptor (EGFRvIII) hold promise for improving tumor… 
2011
2011
Targeting epidermal growth factor receptor to optimize chemoradiotherapy in locally advanced head and neck cancer: has biology been taken into account?
TO THE EDITOR: Nonsurgical treatment of locally advanced squamous cell carcinoma of the head and neck (SCCHN) has progressed over… 
2010
2010
An open-label, randomized, phase III trial of zalutumumab, a human monoclonal EGF receptor (EGFr) antibody, versus best supportive care, in patients with noncurable squamous cell carcinoma (SCCHN) of…
LBA5506 Background: Zalutumumab is a novel, fully human IgG1 mAb targeting the EGFr that has shown encouraging activity in SCCHN… 
2010
2010
Role of ADCC in the in vivo antitumor effects of zalutumumab, a human anti-EGF receptor antibody.
e13102 Background: Zalutumumab (HuMax-EGFr, clone-2F8), a fully human IgG1 EGFR antibody, currently in phase III clinical trials… 
Review
2009
Review
2009
Current situation of zalutumumab
Background: Increased EGFR expression has been observed in many tumours. This overexpression usually correlates with a more… 
2009
2009
Phase I trial of zalutumumab and irinotecan in metastatic colorectal cancer patients who have failed irinotecan- and cetuximab-based therapy.
e15028 Background: Zalutumumab is a novel human IgG1 anti-EGFR mAb. We investigated the safety of zalutumumab and irinotecan in… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)